1) 日本透析医学会統計資料 わが国の慢性透析療法の現況 (2018 年透析導入患者の動態)
2) Husain S, Raza K, Pilewski JM, Zaldonis D, Crespo M, Toyoda Y, Shutt K, Spichty K, Bentlejewski C, Pakstis DL, Carey ME, McCurry KR, Zeevi A. Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection. Transplantation. 2009;87:1852-1857.
3) Sánchez-Velasco P, Rodrigo E, Valero R, Ruiz JC, Fernández-Fresnedo G, López-Hoyos M, Piñera C, Palomar R, Leyva-Cobián F, Arias M. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant. 2008;22:55-60.
4) Kobashigawa JA, Kiyosaki KK, Patel JK Kittleson MM, Kubak BM, Davis SN, Kawano MA, Ardehali AA. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant. 2010;29:504-508.
5) Sugiyama K, Tsukaguchi M, Toyama A, Satoh H, Saito K, Nakagawa Y, Takahashi K, Tanaka S, Onda K, Hirano T. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor. Exp Clin Transplant. 2014;12:195-199.
6) Israeli M, Klein T, Sredni B, Avitzur Y, Mor E, Bar-Nathen N, Steinberg R, Dinari G, Shapiro R. ImmuKnow: a new parameter in immune monitoring of pediatric liver transplantation recipients. Liver Transpl. 2008;14(6):893-898.
7) Hirano T, Oka K, Takeuchi H, Sakurai E, Matsuno N, Tamaki T, Kozaki M. Clinical significance of glucocorticoid pharmacodynamics assessed by antilymphocyte action in kidney transplantation. Marked difference between prednisolone and methylprednisolone. Transplantation. 1994;57:1341-1348.
8) Sugiyama K, Satoh H, Saito K, Takahashi K, Saito N, Hirano T. Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Transpl Int. 2005;18:590-595.
9) Sugiyama K, Isogai K, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Saito N, Hirano T. Cyclosporine pharmacological efficacy estimated by lymphocyte immunosuppressant sensitivity test before and after renal transplantation. J Clin Pharm Ther. 2009;34: 539-545.
10) Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Hirano T. The pharmacological efficacy of mycophenolic acid before and after renal transplantation as estimated by the lymphocyte immunosuppressant sensitivity test (LIST). Immunopharmacol Immunotoxicol. 2010;32:430-436.
11) Sugiyama K, Isogai K, Horisawa S, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Hirano T. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab. Cell Transplant. 2012;21;565-570.
12) Sugiyama K, Isogai K, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Hirano T. Clinical significance of the pharmacological efficacy of tacrolimus estimated by the lymphocyte immunosuppressant sensitivity test (LIST) before and after renal transplantation. Cell Med. 2012;3(1-3):81-88.
13) Hatanaka H, Ishizawa H, Nakamura Y. Hiroshige, Tadokoro H, Tanaka H, Onda K, Sugiyama K, Hirano T. Effects of vitamin K3 and K5 on proliferation, cytokine production, and regulatory T cell-frequency in human peripheral- blood mononuclear cells. Life Sci. 2014 Mar 18;99(1-2):61-8.
14) Suzuki Y, Nawata H, Soen S, Fujiwara S, Nakayama H, Tanaka I, Ozono K, Sagawa A, Takayanagi R, Tanaka H, Miki T, Masunari N, Tanaka Y. Guidelines on the management and treatment of glucocorticoid- induced osteoporosis of the Japanese Society for Bone and Mineral Research : 2014 update. J Bone Miner Metab. 2014;32:337-350.
15) Ho LJ, Chang DM, Lee TC, Chang ML, Lai JH.. Plant alkaloid tetrandrine downregulates protein kinase C-dependent signaling pathway in T cells. Eur J Pharmacol. 1999 19;367(2-3):389-98.
16) Liu T, Liu X, Li W. Tetrandrine, a Chinese plant-derived alkaloid, is a potential candidate for cancer chemotherapy. Oncotarget. 2016; 7: 40800-40815.
17) Bhagya N, Chandrashekacr KR. Tetrandrine-A molecule of wide bioactivity. Phytochemistry. 2016;125:5-13.
18) Bhagya N, Chandrashekar KR. Tetrandrine and ancer-An overview on the molecular approach. Biomed Pharmacother. 2018;97:624-632
19) Xu W, Meng K, Kusano J, Matsuda H, Hara Y, Fujii Y, Suzuki S, Ando E, Wang X, Tu Y, Tanaka S, Sugiyama K, Yamada H, Hirano T. Immunosuppressive efficacy of tetrandrine combined with methylprednisolone against mitogen-activated peripheral blood mononuclear cells of haemodialysis patients. Clin Exp Pharmacol Physiol 2017;44(9):924- 931.
20) CKD ステージ G3b~5 患者のための腎障害進展予防とスムーズな腎代替療法への移行に向けた診療ガイドライン 2015,平成 26 年度厚生労働科学研究委託事業(難治性疾患等実用化研究事業(腎疾患実用化研究事業))慢性腎不全診療最適化による新規透析導入減少実現のための診療システム構築に関する研究班
21) Kohei N, Sawada Y, Hirai T, Omoto K, Ishida H, Tanabe K. Influence of dialysis duration on the outcome of living kidney transplantation. Ther Apher Dial.2014;18:481-8.
22) Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis. 2005;41:281-288.
23) Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003;26:510-513.
24) Redaelli B. Hydroelectrolytic equilibrium change in dialysis. J Nephrol. 2001;14:S7-11.
25) Dounousi E1, Papavasiliou E, Makedou A, Ioannou K, Katopodis KP, Tselepis A, Siamopoulos KC, Tsakiris D. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis. 2006;48(5):752-60.
26) Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233.
27) Chung BH, Kim KW, Sun IO, Choi SR, Park HS, Jeon EJ, Kim BM, Choi BS, Park CW, Kim YS, Cho ML, Yang CW. Increased interleukin-17 producing effector memory T cells in the end-stage renal disease patients. Immunol Lett. 2012;141(2):181-189.
28) Sugiyama K, Isogai K, Toyama A, Satoh H, Saito K, Nakagawa Y, Tasaki M, Takahashi K, Saito N, Hirano T. Pharmacodynamic parameters of immunosuppressive drugs are not correlated with age, duration of dialysis, percentage of lymphocytes or lymphocyte stimulation index in renal transplant recipients. Biol Pharm Bull. 2008;31(11):2146-2149.
29) Saag KG, Emkey R,Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Malice MP, Czachur M, Daifotis AG. Alendronate for the prevention and treatment of glucocorticoid- induced osteoporosis. Glucocorticoid- Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-299.
30) Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain HH, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Siminoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 2001;44:202-211
31) Eastell R, Devogelaer JP, Peel NF, Chines AA, Bax DE, Sacco-Gibson N, Deuxchaisnes CN, Russell RG. Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients. Osteoporos Int. 2000;11:331-337.
32) Shikano K, Kaneko K, Kawazoe M, Kaburaki M, Hasunuma T, Kawai S. Efficacy of vitamin K2 for glucocorticoid-induced osteoporosis in patients with systemic autoimmune diseases. Intern Med. 2016;55:1997-2003.
33) Ebina K, Shi K, Hirao M, Kaneshiro S, Morimoto T, Koizumi K, Yoshikawa H, Hashimoto J. Vitamin K2 administration is associated with decreased disease activity in patients with rheumatoid arthritis. Mod Rheumatol. 2013;23:1001- 1007.
34) Lang CL, Wang MH, Hung KY, Hsu SH, Chiang CK, Lu KC. Correlation of interleukin-17- producing effector memory T cells and CD4 + CD25 + Foxp3 regulatory T cells with the phosphate levels in chronic hemodialysis patients. Sci World J. 2014;2014(593170):9.
35) Xu W, Meng K, Tud Y, Tanaka S, Onda K Sugiyama K, Hirano T, Yamada H. Tetrandrine potentiates the glucocorticoid pharmacodynamics via inhibiting P-glycoprotein and mitogen-activated protein kinase in mitogen-activated human peripheral blood mononuclear cells. Eur J Pharmacol. 2017 Jul 15;807:102-108.
36) Liu ZL, Onda K, Tanaka S, Toma T, Hirano T, Oka K. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA. Cancer Chemother Pharmacol. 2002;49:391-397.
37) Liu ZL, Hirano T, Tanaka S, Onda K, Oka K. reversal of P-glycoprotein- mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells. J Pharm Pharmacol. 2003;55:1531-1537.
38) Wang TX, Yang XH. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin- resistance in human breast cancer (MCF-7/DOX) cells. Yao Xue Xue Bao. 2008;43:461-466.
39) Li S, Ling L, Teh B,Seow W, Thong Y. Anti-inflammatory and immunosuppressive properties of the bis-benzylisoquinolines:in vitro comparisons of tetrandrine and berbamine. Int J Immunopharmacol 1989;11:395-401.
40) 安田耕太郎, 茂呂光男, 赤須通範, 大西明弘:臨床薬理,1989; 20(4), 741-749.